Digital Decision Aids Could Close the Cancer Prevention Gap for Disadvantaged Women

Cancer remains one of the leading causes of premature death among women worldwide, and the burden of that toll is not distributed evenly. Women who live in conditions of social disadvantage—shaped by limited income, lower educational attainment, unstable housing, language barriers, or restricted access to health services—consistently show lower participation in cancer screening programs and higher mortality from cancers that could have been detected or prevented earlier. A new research effort published in PLOS One now sets out to systematically map one of the most promising yet underexplored tools for closing this gap: digital patient decision aids designed specifically for cancer prevention in socially disadvantaged women.

The study, led by Emmanuelle Lüthi and colleagues at institutions in Switzerland, is not itself a trial of a new tool. Instead, it is a scoping review protocol—a rigorous, pre-registered plan for how the team will search, screen, and analyze all available evidence on the topic. Scoping reviews occupy a distinctive place in the hierarchy of health research. Rather than pooling numbers statistically, as a meta-analysis would, they chart the breadth of a field: what tools exist, how they were built, who they were tested on, and how their effects were measured. For an emerging area like digital decision support for underserved populations, that mapping exercise is often the essential first step before any definitive trials can be designed.

Patient decision aids, abbreviated PtDAs in the research literature, are structured materials that help people weigh options for a health decision by laying out the benefits, risks, and uncertainties of each choice alongside their own values and preferences. In cancer prevention, such decisions are everywhere. Should a woman with a family history of breast cancer begin mammography earlier than standard guidelines suggest? Should she opt for HPV-based cervical screening, and at what interval? Should she consider genetic testing, lifestyle interventions, or vaccination? The best available evidence shows that decision aids improve knowledge of options, sharpen the accuracy of risk perceptions, and reduce the decisional conflict and passivity that often leave patients defaulting to whatever their clinician mentions first—or nothing at all.

The digital dimension adds both power and peril. Web-based and app-based decision aids can be updated instantly, delivered at scale, tailored to a user’s literacy level or language, and embedded in telehealth platforms or patient portals. During and after the COVID-19 pandemic, the accelerated shift toward remote care made digital tools the default channel for preventive health communication in many systems. Yet the same shift risks deepening the very inequities these tools promise to reduce. Women without reliable internet access, smartphones, digital skills, or the spare time and private space to engage with an online module may be systematically excluded. This tension—digital health as equalizer versus digital health as amplifier of disadvantage—sits at the heart of the review’s rationale.

The protocol is explicit about what will count as evidence. To be included, a digital patient decision aid must target socially disadvantaged women aged 18 to 75, address cancer prevention rather than treatment, and meet the minimum criteria established by the International Patient Decision Aid Standards, a widely used framework that requires, among other things, that the aid present options, describe potential benefits and harms, and clarify what is known and unknown. The team will consider quantitative studies, qualitative research, and gray literature—reports, evaluations, and program documents that never appear in peer-reviewed journals but often contain the richest descriptions of how tools were actually developed and deployed in community settings.

The search strategy itself reflects the methodological standards of the Joanna Briggs Institute, one of the leading bodies for evidence synthesis. The reviewers will run a comprehensive three-step search across MEDLINE, CINAHL, Embase, Web of Science, and the Cochrane Library, supplemented by Google Scholar and targeted gray-literature sources. Notably, they will include studies in any language, a decision that matters enormously for equity research: excluding non-English publications would systematically discard evidence from the low- and middle-income settings where socially disadvantaged women form the majority of the population. Citations will be imported into Rayyan, a screening platform, and two independent reviewers will conduct study selection, data extraction, and analysis in parallel, with disagreements resolved through discussion—a standard safeguard against individual bias.

Once the evidence is assembled, the team plans to summarize it using tables and descriptive content analysis, organized around three axes: the characteristics of the digital aids themselves, the processes by which they were developed, and the methods used to evaluate them. Each axis carries scientific weight. Characteristics—platform, interactivity, tailoring, language options, theoretical grounding—determine who can actually use a tool. Development processes reveal whether disadvantaged women were involved as co-designers or merely as end users, a distinction that participatory health research has shown to be decisive for uptake. Evaluation methods indicate whether the field has measured what matters: not just clicks and completion rates, but screening uptake, informed choice, and decisional confidence among the women the tools were meant to serve.

The reporting and dissemination plan is unusually broad for a protocol at this stage. The review will follow the PRISMA-ScR guidelines, the accepted reporting standard for scoping reviews, and the team has registered the protocol with the Open Science Framework, making the plan publicly inspectable before any results exist. Findings are intended for submission to an international peer-reviewed journal and for presentation at conferences spanning cancer prevention, shared decision-making, digital health, and the health of socially disadvantaged women. Crucially, the authors commit to sharing results not only with clinicians and public health stakeholders but also with disadvantaged communities and their networks—an acknowledgment that research about a population is incomplete until the population can act on it.

Why does this matter now? Preventable cancers continue to claim lives at rates that track social gradients with uncomfortable precision. Screening participation for cervical and breast cancer is repeatedly shown to be lower among women facing poverty, migration-related barriers, or limited health literacy, and mortality follows. Decision aids are not a substitute for the structural fixes—insurance coverage, transportation, paid time off, culturally competent care—but they address a quieter barrier: the moment in a consultation or on a screen when a woman must decide whether prevention is for her, and whether she understands enough to choose. If digital tools can be designed with rather than for disadvantaged women, they may convert a moment of confusion into a moment of agency.

The protocol also signals a maturing of the digital health equity field. Rather than rushing to build another app, the researchers are first asking what the existing evidence actually shows, where the gaps lie, and which design and evaluation practices have been validated. That discipline—mapping before building, registering before searching, involving communities before publishing—offers a template for how health technology research can serve populations that have historically been last in line. The results of the review, once complete, will give clinicians, developers, and policymakers their first systematic picture of whether digital decision support for cancer prevention is genuinely reaching the women who need it most, or whether the digital revolution in preventive care is still passing them by.

Subject of Research: A scoping review protocol mapping digital patient decision aids for cancer prevention in socially disadvantaged women

Article Title: Digital patient decision aids for cancer prevention in socially disadvantaged women: A scoping review protocol

Article References: Lüthi, E., Pittet, O., Montagnese, J., Freund, R., Selby, K., Grazioli, V. S., Brauchli, T., & Durand, M.-A. (2026). Digital patient decision aids for cancer prevention in socially disadvantaged women: A scoping review protocol. PLOS One, 21(10), e0359332. https://doi.org/10.1371/journal.pone.0359332

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0359332

Keywords: patient decision aids, cancer prevention, health equity, digital health, scoping review, socially disadvantaged women, shared decision-making, cancer screening, PLOS One, evidence synthesis, PRISMA-ScR, digital divide